Automation in the bioanalytical laboratory
Increased uptake of automated technology within the pharmaceutical and biotechnology community, combined with the reliance on automated technologies through the COVID-19 pandemic has prompted an investigation into the role of automation within drug development. The advantages of automation are well documented; improvements in data integrity, reduced error rate and increased sample throughput are all realized benefits of automated workflows.
This webinar will discuss the extent of automation within bioanalysis currently, the practicality of automated technologies for extraction methods and ligand binding assays, and future projections for bioanalytical automation.
What will you learn?
- Thoughts and perspectives of automation in bioanalysis
- Benefits and impact of automation
- Future outlooks on automation development
Who may this interest?
- Pharmaceutical and biotechnology professionals
- Instrument developers and manufacturers
- Contract research organizations
- Laboratory managers
- Bench scientists
Speakers
Lynne Le Sauteur
Vice President, Laboratory Sciences
Altasciences
Dr. Le Sauteur joined Altasciences in September 2019, and leads a team of over 260 specialists involved in bioanalysis, immunogenicity, biomarkers, and immunotoxicity assessments for large and small molecules, oligonucleotides and gene therapy.
She received her PhD in Pharmacology and Therapeutics from McGill University and has over 20 years’ experience in biologic drug development. Prior to joining Altasciences, she was Director of Downstream Processing and Analytics, as well as Program Leader, Biologics and Biomanufacturing, for the Human Health Therapeutics Research Center at the National Research Council of Canada (NRC), where she led numerous teams and initiatives to discover, biomanufacture, and characterize novel biologics for unmet needs, in collaboration with different biopharmaceutical companies.
Prior to the NRC, Lynne worked at Charles River Laboratories, where she established the Immunology Department, and led the scientific and strategic growth of that group from one to over 80 employees, effectively delivering expertise to sponsors in advancing numerous biologics through the drug development value chain.
Frédéric Massé
Senior Director, Bioanalytical Operations
Altasciences
Frédéric Massé joined Altasciences in September 2021 and is currently Senior Director, Bioanalytical Operations. He leads a team responsible for sample management, process optimization and automation. Frederic received his MSc in Molecular Biology / Biochemistry from the University of Montreal and has more than 20 years in pharmaceutical drug discovery.
Prior to joining Altasciences, he was managing the High Throughput Facility at the Human Health Therapeutics Research Center at the National Research Council of Canada (NRC) where he was responsible for implementing automated platforms, managing innovative projects in bioanalysis, and improving processes such as sample management and LIMS to support collaboration with different biopharmaceutical companies.
Prior to NRC, Frederic worked at Merck in Canada and the US as Director of Assay Operations within the In Vitro Pharmacology department where he was leading the sample management and high throughput screening teams to support various Drug Discovery programs.
Ludovicus Staelens
Director Translational Biomarkers and Bioanalysis, Head of Bioanalysis Belgium at UCB (Belgium)
In association with
